Evidence map›Paper›PMID 40847199›Full record

SynthesisChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025

Stem cell therapy in neonates with hypoxic-ischemic encephalopathy: a systematic review and meta-analysis.

Prateek Kumar Panda, Ananthanarayanan Kasinathan, Pragnya Panda, Lesa Dawman, Aditi Gupta, Vivek Singh Malik, Indar Kumar Sharawat, Meenu Singh

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Prateek Kumar PandaPediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India, 249203.
Ananthanarayanan KasinathanDepartment of Pediatric Neurology, Rainbow Children's Hospital, Chennai, Tamilnadu, India.
Pragnya PandaDepartment of Neurology, All India Institute of Medical Sciences, Uttar Pradesh, Raebareli, India, 229405.
Lesa DawmanDepartment of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India, 160012.
Aditi GuptaPediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India, 249203.
Vivek Singh MalikDepartment of Telemedicine, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India, 249203.
Indar Kumar SharawatPediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India, 249203. sherawatdrindar@gmail.com.
Meenu SinghExecutive Director and CEO, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India, 249203.

Funding

Indian Council of Medical Research EOI/syst.review/RMRU/2023/19/BMS
6 · The paper itself

Abstract

backgroundApart from therapeutic hypothermia, no treatment is approved for neonates with hypoxic-ischemic encephalopathy (HIE). Stem cell therapy is a promising option, with a few studies conducted in recent years.

methodsThis systematic review assessed pooled 12-month survival and neurodevelopmental outcomes in neonates with HIE receiving stem cell therapy. Secondary outcomes included survival with favorable neurodevelopment, seizures during hospitalization, discharge on antiseizure medication (ASM), and 100% oral feeding. Both controlled and uncontrolled trials were included.

resultsFour studies, including one quadruple-blinded randomized-controlled trial (RCT), met the inclusion criteria, comprising 153 neonates, with 52 in the stem cell therapy group and 101 in the standard care group. Among those receiving stem cell therapy, 46 neonates received umbilical cord blood-derived stem cells, while 6 received human cord tissue mesenchymal stem cells. The pooled 12-month survival rate in the stem cell group was 92% (95% CI: 82%-98%, I

conclusionStem cell therapy appears safe and may improve neurodevelopmental outcomes in neonates with HIE. However, larger, more robust RCTs are needed before universal recommendations can be made.

Indexed as

Hypoxia-Ischemia, BrainStem Cell TransplantationHumansInfant, NewbornRandomized Controlled Trials as TopicHypoxiaNeonatesNeurodevelopmental outcomeStem cellSurvival

Identifiers

PMID40847199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.